The SEC enforcement action, finalized in December 2024, followed findings that the company misrepresented regulatory risks associated with its Alaris device. On February 6, 2020, the firm revealed a need for new FDA clearance and a halt in sales, causing shares to drop approximately 12%. While the company settled without admitting or denying these findings, it agreed to pay the $175 million penalty to compensate affected shareholders.
Investors Eligible for Share of $175M Becton Fair Fund
Investors who held Becton, Dickinson and Company common stock between February 5, 2019, and February 5, 2020, are now eligible to file claims for a portion of a $175 million settlement. The fund stems from SEC charges regarding misleading disclosures about the company's Alaris infusion pump risks.
To participate in the distribution, claimants must submit documentation to JND Legal Administration by December 13, 2026. Forms are available at www.BectonFairFund.com, where electronic filing is encouraged. Brokers and other nominees holding records of these transactions are required to notify beneficial owners within 14 days of receiving the official notice packet. Further inquiries regarding eligibility can be directed to the administrator at (866) 910-1105.
Comments (0)
No comments yet. Be the first!